

CERTIFICATE OF MAILING

I hereby certify that this paper and every
paper referred to therein as being enclosed
is being deposited with the U.S. Postal Ser-
vice as first class mail, postage prepaid,
in an envelope addressed to: Commissioner of
Patents & Trademarks, Washington, DC 20231.
on Oct 17, 2000 (Date of Deposit)

10/17/00
Date

S. Hsu
Name

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-713-B)

In re Application of:)
Chad A. Mirkin, et al.)
Serial No.: 09/240,755) Group Art Unit: 1643
Filed: June 29, 1999) Examiner: TBA
For: NANOPARTICLES HAVING)
OLIGONUCLEOTIDES)
THERETO AND USES THEREFOR)

Asst. Commissioner for Patents
Washington, DC 20231

POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST
(REVOCATION OF PRIOR POWERS)

As assignee of record of the entire interest of the above identified

application
 patent

REVOCATION OF PRIOR POWERS OF ATTORNEY

all powers of attorney previously given are hereby revoked and

NEW POWER OF ATTORNEY

The undersigned hereby appoints all of the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and directs that all correspondence be addressed to that Customer Number:

Customer Number: 020306
Principal attorney or agent: Emily Miao
Telephone number: 312-913-0001

Assignee of Entire Interest:

Name: Nanosphere, Inc.
Address: 1801 Maple Ave., Evanston, IL 60201

EVIDENCE AND CERTIFICATION OF CHAIN OF TITLE


Recorded in PTO on _____
Reel _____
Frame _____

Attached copy of Assignment filed 5/18/00.

ASSIGNEE CERTIFICATION

In accordance with 37 C.F.R. § 3.73 the assignee hereby certifies that the evidentiary documents with respect to its ownership have been reviewed and that, to the best of assignee's knowledge and belief, title is in the assignee seeking to take this action.

Date: Sept 28, 2000


Name: Chad A. Mirkin
Title: President of Nanosphere, Inc.

RULE 63 (37 CFR § 1.63)
DECLARATION FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled "NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO AND USES THEREFOR", the specification of which has been prepared and filed on January 29, 1999, receiving Serial No. 09/240,755, and further identified as Attorney File No. 4149-1-1.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability in accordance with 37 CFR 1.56(a) and (b) as set forth on the attached sheet indicated Page 3 hereof and which I have read.

I hereby claim priority benefits under 35 U.S.C. 119(e) of any provisional application(s) for patent listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information material to patentability in accordance with 37 CFR 1.56(a) and (b) which occurred between the filing date(s) of the prior application(s) and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
60/031,809	July 29, 1996	Proceedings Concluded

I hereby claim the benefit under 35 U.S.C. 120/365 of all United States and PCT international applications listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information material to patentability in accordance with 37 CFR 1.56(a) and (b) which occurred between the filing date(s) of the prior application(s) and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
PCT/US97/12783	July 21, 1997	Proceedings Concluded

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(1) Inventor's Signature Chad A Mirkin Date 3/29/99

Inventor's Name Chad A. Mirkin
Citizenship: USA
Residence: ~~9744 Crawford Avenue~~ 111 16th St.
~~Skokie, Illinois 60076~~ Wilmette, IL 60091
Post Office Address: Same as Residence

(2) Inventor's Signature Robert Letsinger Date 3/29/99

Inventor's Name: Robert L. Letsinger
Citizenship: USA
Residence: 316 Third Street
Wilmette, Illinois 60091
Post Office Address: Same as Residence

(3) Inventor's Signature Robert Mucic Date 4-1-99

Inventor's Name: Robert C. Mucic
Citizenship: USA
Residence: ~~2121 Ridge Ave., Apt. 2J~~ 1600 Bel Aire Dr.
~~Evanston, Illinois 60201~~ Glendale, CA 91201
Post Office Address: Same as Residence

(4) Inventor's Signature James J. Storhoff Date 3-29-99

Inventor's Name: James J. Storhoff
Citizenship: USA
Residence: ~~2133 1/2 Ridge Avenue, Apt. 2D~~ 2121 Ridge Ave, Apt. 2J
Evanston, Illinois 60201
Post Office Address: Same as Residence

(5) Inventor's Signature Robert Elghanian Date 3/29/99

Inventor's Name: Robert Elghanian
Citizenship: USA
Residence: 8503 W. Catherine Avenue, Apt. 602
Chicago, Illinois 60656
Post Office Address: Same as Residence

37 CFR §1.56(a) and (b)
DUTY TO DISCLOSE INFORMATION MATERIAL
TO PATENTABILITY

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

(1) prior art cited in search reports of a foreign patent office in a counterpart application, and

(2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

(1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or

(2) It refutes, or is inconsistent with, a position the applicant takes in:

(i) Opposing an argument of unpatentability relied on by the Office, or

(ii) Asserting an argument of a patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.*

*Note, 37 CFR §1.97(h) states: "The filing of an information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56(b)."